News

Histofy, an AI-driven leader in histopathology solutions, is excited to announce a new collaboration with Haukeland University Hospital (HUH), one of Norway’s premier medical institutions. The partnership aims to address a critical challenge in modern pathology: the classification of colon polyps. This initiative promises to improve efficiency, assisting pathologists in making quicker assessments for colorectal cancer prevention. Bergen, Norway and Coventry, UK (14 October 2024) – Colon polyps are abnormal growths in the colon that, if left untreated, can develop into colorectal cancer, the second leading cause of cancer deaths worldwide. Efficient classification of these polyps is vital for determining the appropriate surveillance and treatment pathway and improving patient outcomes. Yet, the current classification process is time-consuming and heavily reliant on subjective interpretation, posing risks for misdiagnosis. Through this collaboration, Histofy will lead the development of a cutting-edge AI tool using clinical data and expertise from HUH to classify colon polyps more efficiently. The groundbreaking technology will empower HUH’s pathology team, streamline workflows and deliver faster, more consistent results in the early detection of potential cancers. The Norwegian Colorectal Screening Program provides funding support for the project. “This partnership represents a leap forward for pathology. By integrating AI into our diagnostic process, we anticipate not only more efficient workflows but also faster, more standardized diagnostics, which will ultimately benefit our patients,” said  Professor Elisabeth Wik, the head of the pathology department at Haukeland University Hospital. “We anticipate not only more efficient workflows but also faster, more standardized diagnostics, which will ultimately benefit our patients” “We are thrilled to partner with Haukeland University Hospital, a recognised leader in clinical research and patient care,” said Professor David Snead, CMO of Histofy. “This collaboration aligns with our mission to harness AI to solve critical healthcare challenges and further proves the clinical value of AI in pathology.” The project will focus on validating AI algorithms developed by Histofy and incorporating them into HUH’s diagnostic pipeline. This includes using AI to differentiate between various types of polyps and identify subtle features that might be overlooked by traditional methods. Ultimately, the collaboration will not only reduce diagnostic time but also improve treatment selection, surveillance plans and patient outcomes. Additionally, by reducing patient waiting time, it will help alleviate the sense of uncertainty, anxiety, and fear, as most polyps are truly benign. About Histofy Histofy is a cutting-edge medical AI startup specializing in pathology AI solutions. Their data-efficient transparent AI solutions ensure powerful performance with minimal data, making their solutions trustworthy and scalable for a wide range of healthcare settings. About Haukeland University Hospital Haukeland University Hospital is one of Norway’s largest hospitals and a leader in clinical innovation. Pathology diagnostics at HUH and across the entire Western Norway Health Region, including 3 additional pathology departments, is fully digitized providing a solid foundation for the implementation of AI tools. As a key medical center in Scandinavia, HUH is committed to advancing patient care through research, innovation, and collaboration. For more information, please contact Dr Simon Graham at s.graham [at] histofy [dot] ai. Simon Graham Chief Technology Officer

Histofy, a leader in the development of transparent AI solutions for pathology, proudly announces the formation of its Scientific Advisory Board. This milestone reflects Histofy’s commitment to integrating world-class expertise into its innovative product line, ensuring real-world impact. Coventry, UK (22nd July 2024) – Histofy is pleased to introduce its new Scientific Advisory Board, comprising five esteemed leaders across pathology and oncology. The Board shall meet regularly with the Histofy core team, to offer guidance and feedback, and to identify emerging needs within the pathology sector. Advisory Board Composition The board members are: Professor Mark Arends – Professor of Pathology, Head of Pathology, and Co-director of the Centre for Comparative Pathology at the University of Edinburgh. Professor Ali Khurram – Professor and Honorary Consultant in Oral and Maxillofacial Pathology at the University of Sheffield, and Founder and Lead of the NeoPATH Research Group. Dr Sabine Tejpar – Associate Professor in the Faculty of Medicine, Head of Digestive Oncology, and Head of the Subdivision of Molecular Genetics of Colorectal Tumours at KU Leuven. Dr Jonathan Williams – Head of Pathology and Senior Lecturer in Veterinary Anatomic Pathology at the Royal Veterinary College. Fellow of the Higher Education Academy (FHEA), Diplomate of the European College of Veterinary Pathologists (ECVP), and a Royal College of Veterinary Surgeons (RCVS) member. “I am delighted at the prospect of discussing real-world problems with our newly formed Scientific Advisory Board” Nasir Rajpoot, CEO & CSO of Histofy, expressed his enthusiasm, saying, “I am delighted at the prospect of discussing real-world problems with our newly formed Scientific Advisory Board. Their feedback will be invaluable in shaping our future.” Sabine Tejpar added, “I am excited to join Histofy’s Scientific Advisory Board because the integration of AI in pathology holds immense potential for improving diagnostic accuracy and efficiency. I look forward to contributing to the development of cutting-edge solutions that can transform patient care.” Mark Arends remarked, “Joining Histofy’s Scientific Advisory Board is a great opportunity to apply advanced AI techniques to real-world pathology challenges. I am keen to collaborate with the team as the integration of AI in pathology holds great promise for streamlining pathology practice, ultimately improving the accuracy of diagnoses and therefore, making a huge difference to the outcome.” Ali Khurram stated, “I am eager to collaborate with the team to push the frontiers of what AI can achieve in medical diagnostics. Being a part of Histofy’s Scientific Advisory Board is a unique opportunity to apply advanced techniques to help tackle challenges within pathology.” About Histofy Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care. With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings. Prof David Snead Chief Medical Officer

Lumiares, a Belgium-based healthtech venture capital fund, announces an investment in Histofy, a University of Warwick spin-out dedicated to the creation of transparent AI solutions for cellular pathology. Ghent, Belgium and Coventry, UK (10th July 2024) – Lumiares takes great pride in announcing its investment in Histofy, a spin-out from the distinguished Tissue Image Analytics (TIA) Centre at the University of Warwick. Histofy excels in crafting AI technologies that enhance the accuracy of diagnostics and treatment planning for intricate diseases like cancer, while expediting biomarker discovery for the pharmaceutical sector. Histofy is led by a top team, including CEO & CSO Nasir Rajpoot, an internationally recognised expert in AI-based pathology research. Professor Rajpoot remarks: “I am thrilled to announce our partnership with Lumiares, a Belgian investment firm with profound expertise in pathology, oncology and the medtech industry. The wealth of experience that Lumiares’ partners and co-investors bring to Histofy is invaluable. This partnership not only underscores our commitment to pioneering advancements in AI for cellular pathology but also significantly enhances our capacity to innovate and expand.” Joining Lumiares in this investment are three experienced clinicians, including Dr. Romaric Croes, pathologist and co-investor in Histofy. Croes shares, “We, as pathologists, are convinced of Histofy’s profound potential to integrate explainable and transparent AI into anatomical pathology practices cost-effectively. This pioneering technology extends beyond mere screening to encompass predicting responses to targeted therapies using standard stainings, thus eliminating the necessity for expensive supplementary tests.” “We, as pathologists, are convinced of Histofy’s profound potential to integrate explainable and transparent AI into anatomical pathology” Filip Vandamme, managing partner of Lumiares, echoes this sentiment, highlighting the alignment between Histofy and the fund’s strategic vision: “At Lumiares, we actively seek out promising startup teams across Europe that blend unique clinical benefits, innovative technology, and a scalable business model. Following the advancements in radiology, pathology stands as the next frontier for AI’s transformative impact. Histofy has already demonstrated very promising results in the UK. Together with our co-investors, we eagerly anticipate facilitating their expansion across Europe.” Histofy CMO David Snead, a leader in digital pathology, states: “We are delighted to have received this investment into Histofy. Lumiares are an extremely knowledgeable investment team, who understand the enormous potential for computational pathology to improve outcomes and services for patients, particularly in oncology. We look forward to working with the team at Lumiares and building on the experience and expertise they have to realise this potential across Europe and globally.” About Histofy Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care. With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings. About Lumiares Lumiares is a pre-seed/seed venture capital fund focused on digital health. Lumiares has made investments in AI startups in domains such as Parkinson’s and nuclear medical imaging. The fund is based in Belgium and has a European focus. Lumiares leverages its network of shareholders (of which more than 50% are clinicians) and experts to accelerate the time-to-market of its portfolio companies and scale them internationally. By Nasir Rajpoot Chief Executive Officer & Chief Scientific Officer

Histofy, a biomedical technology company specialising in AI solutions for pathology, proudly announces a partnership with Indica Labs, a leader in AI-powered image analysis and collaborative image management platforms. This strategic alliance marks a significant milestone, aiming to seamlessly integrate Histofy’s advanced AI tools into the HALO AP® platform, developed by Indica Labs. Birmingham, UK and Albuquerque, NM, US (3 June 2024) – Indica Labs and Histofy have come together in a collaboration aimed at bringing Histofy’s cutting-edge AI tools into clinical practice via the established HALO AP® platform1. The partnership facilitates the integration of Histofy tools into clinical practice, placing cutting-edge AI in the hands of pathologists. HALO AP® is an AI-powered, pathologist-driven diagnostic pathology platform that enables primary diagnosis and other routine workflows in anatomic pathology with a CE-IVDR mark in the EU, Switzerland, and the UK, demonstrating its compliance with key regulatory standards. Similarly, HALO AP Dx2 is a pathologist-centric platform that has recently obtained FDA clearance for primary diagnosis in the United States. “We are thrilled to partner with Histofy to bring additional state-of-the-art AI solutions to our HALO AP® platform” “At Histofy, we are committed to advancing the field of pathology through innovative AI technologies,” remarked Dr Simon Graham, CTO at Histofy. “The integration of Histofy’s AI tools into HALO AP® holds great promise for the pathology community. By seamlessly integrating with HALO AP®, Histofy’s tools will augment clinical workflows, empowering pathologists with enhanced diagnostic capabilities and efficiency gains.” “We are thrilled to partner with Histofy to bring additional state-of-the-art AI solutions to our HALO AP® platform,” stated Eric Runde, Chief Operating Officer at Indica Labs. “This collaboration showcases our commitment to providing pathologists with cutting-edge tools for better patient care.” The partnership between Histofy and Indica Labs represents a paradigm shift in pathology, leveraging the power of AI to revolutionise diagnostic processes and ultimately improve patient outcomes. As the healthcare landscape continues to evolve, this collaboration sets a precedent for future advancements in AI-driven pathology solutions. 1HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the US and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance and certifications with FDA 21 CFR Part 11, HIPAA, and GDPR. 2HALO AP Dx (K232833) is FDA-cleared for primary diagnostic use with the Hamamatsu NanoZoomer® S360MD Slide scanner in the US. In addition, HALO AP Dx provides built-in compliance and certifications with FDA 21 CFR Part 11 and HIPAA. About Histofy Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care. With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings. About Indica Labs Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionises quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organisations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery. By Nasir Rajpoot Chief Executive Officer & Chief Scientific Officer

Histofy, a leading biomedical technology  company developing transparent AI solutions for pathology, announces a partnership with Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, enabling laboratories across the world to access Histofy’s cutting-edge AI tools. Birmingham, UK (14th February 2024) – Histofy is excited to offer its AI models via the Paige AppLab™, which serves as an extensive marketplace, enabling pathologists to effortlessly browse, trial, and purchase AI tools with just a few clicks. Histofy products will be accessible from within the Paige Platform and FullFocus® viewer, widening the reach of AI in routine practice.  Nasir Rajpoot, Co-Founder, CEO & CSO of Histofy, said, “We are thrilled to announce our collaboration with Paige, a move that marks a significant milestone in our journey towards revolutionising pathology and research with our innovative AI solutions. The partnership opens a highly promising route to market for Histofy, enabling our AI products to reach a wider audience of pathologists and researchers who are already engaged with the advanced capabilities of the Paige Platform.” “The partnership with Paige opens a highly promising route to market for Histofy, enabling our AI products to reach a wider audience” Histofy continues to expand its range of leading AI models and will initially offer MitPro, a tool for next-generation mitosis analysis, and CoBi, a tool for AI-powered colon biopsy screening via the Paige AppLab™.  Professor Rajpoot added, “By integrating our groundbreaking AI tools with Paige’s robust platform, we are poised to bring about a transformative change in the field of pathology. With Paige’s extensive network and platform capabilities, we are confident that our AI solutions will become more accessible to healthcare professionals, ultimately contributing to better patient outcomes and advancing the field of medical research.” Andy Moye, CEO of Paige, said “Paige is dedicated to providing pathologists with cutting-edge tools tailored for real-world clinical use. We are thrilled to partner with Histofy in advancing this mission. The inclusion of Histofy’s MitPro and CoBi tools in the Paige AppLab™ offers a straightforward mechanism for pathologists to incorporate AI into their digital pathology workflows”. Histofy is currently working towards CE-mark under IVDR for both its MitPro and CoBi tools. To find out more, click the button below. Explore Histofy’s range of tools About Histofy Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care. With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings. About Paige Paige uses the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment. By Simon Graham Co-Founder and Chief Technology Officer

Histofy, a leading developer of transparent AI solutions for pathology, proudly introduces MitPro, its cutting-edge AI tool designed for advanced mitosis profiling—a critical component in cancer grading. Birmingham, UK (31st January 2024) –Histofy, a pioneering startup developing AI tools for pathology, unveils MitPro, a solution tailored for the comprehensive counting and profiling of mitosis. The quantification of cells undergoing division within pathology slides, known as mitotic figures, serves as a key indicator of cancer aggressiveness, or grade. This information is instrumental in guiding optimal patient treatment, making mitosis assessment a crucial task. However, traditional mitosis counting is both time-consuming and plagued by poor reproducibility. Histofy addresses these challenges with MitPro, an AI solution that streamlines and extends mitosis profiling.  The tool enhances the current standard of care for grading various cancers, such as breast cancer and sarcomas, by accurately identifying dividing cancer cells. In this context, an elevated count of dividing cells indicates a fast-growing or highly aggressive tumour. Conventionally, pathologists perform this counting manually, but due to time constraints, it is limited to a small portion of the tumour. With the power of AI, MitPro can count these dividing cells more accurately and over the entire tumour, providing a better indication for the cancer grade and leading to enhanced patient care and biomarker identification. Prof Snead, Chief Medical Officer at Histofy, said:  “Despite its paramount importance, mitosis assessment can be laborious and suffers from reproducibility issues. We are thrilled to introduce MitPro, a solution that not only improves current practice, but also enables comprehensive profiling of cell proliferation across the entire tumour.” “MitPro not only improves current practice, but also enables comprehensive profiling of cell proliferation across the tumour” Integration with pathology workflows To facilitate the widespread adoption of AI in practical settings, Histofy is integrating with established pathology image management systems, including Sectra. Dr Simon Graham, Chief Technology Officer at Histofy, said: “By integrating with Sectra, we enable users of the Sectra Digital Pathology Solution to integrate MitPro as part of their regular workflow. We remain dedicated to integrating our technology with various image management systems to broaden the accessibility of our AI tools in real-world practice.” Histofy is presently engaged in the validation of MitPro with early adopters of the tool to showcase its practical utility. While the tool is currently designated for research use only, Histofy is currently working towards CE-mark certification under IVDR. Find out more about MitPro About Histofy Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care. With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings. By Simon Graham Co-Founder and Chief Technology Officer

Histofy, a company specialising in developing transparent AI for pathology, today announces a project to develop an AI-powered system that provides precise quantification and profiling of cancer cells in growth overdrive, in order to enhance patient care. Birmingham, UK (20th March 2023) – Histofy, a UK-based startup developing transparent AI solutions for digital pathology, today announces an industry-academic collaboration with CNAI, a leading AI synthetic data company in Korea, and Korea University to develop MitProfiler, a cloud-based AI solution that profiles mitotic figures in digitised images of cancerous tissue slides. The collaboration is funded by Innovate UK and KAIT under the UK-South Korea Collaborative R&D scheme, which aims to fund collaborative research and development (CR&D) projects focused on industrial research.  Automating Mitosis Detection Powered by advanced award-winning algorithms, MitProfiler will be able to detect mitotic figures from digitised images of tissue slides and quantify tumour proliferation across entire tissue samples, allowing pathologists to assess tumour proliferation more quickly and accurately. Pathologists typically detect mitotic figures by manually counting mitoses in tumour regions, an inherently subjective and time-consuming task that is prone to observer variability. “The MitProfiler product is aimed at enhancing workload efficiency of pathologists” The project will allow rapid adoption of AI-based detection of mitotic figures, helping to drastically reduce the time required for counting. Despite recent developments in computational pathology, there is currently no device on the market that is fully operable in various digital pathology systems across a range of tumour sites. Histofy leads the project with data collection and refinement of their award-winning algorithm, while CNAI will design and develop the cloud architecture. Histofy will also collaborate with Korea University to research and develop domain-invariant methods for mitotic figure detection, allowing the solution to perform well across institutions with different scanner manufacturers and tissue preparation protocols.  Dr Simon Graham, CTO and co-founder of Histofy said: “Histofy is a team of world leading experts in computational pathology, and we are ready to make AI accessible across a range of solutions for the digital pathology market. The MitProfiler product is aimed at enhancing workload efficiency of pathologists, leading to better patient management.”  Wonseop Lee, CEO and founder of CNAI, said: “We are happy to work with Histofy and Korea University in developing MitProfiler for better patient care. This technology has the potential to revolutionise the field of pathology by improving the accuracy and efficiency of tumour analysis. Our extensive MLOps and biomedical research experience will help us to bring this technology to the market and make an impact that matters.” Professor Jin Tae Kwak of Korea University said: “We are thrilled to partner with Histofy and CNAI”. This international collaboration will provide an opportunity to create an innovative AI device that can impact patients suffering from serious diseases.” About CNAI CNAI is Korea’s first AI synthetic data company with extensive research and business experience. Its expertise in synthetic data for AI vision systems helps large corporations develop AI applications in industries including retail, manufacturing, and healthcare. About Korea University Korea University is one of the top institutions of higher education in Korea. The Quantitative Imaging and Informatics Laboratory (QuIIL) at Korea University, led by professor Jin Tae Kwak, is a major contributor of this consortium, which is a research team focussing on the development of advanced AI techniques for medical image analysis. By Simon Graham Co-Founder and Chief Technology Officer

Histofy, a company specialising in AI for pathology, today announces £500K of funding to develop algorithms for endoscopic colon biopsy screening, helping to mitigate the worldwide pathology staffing crisis.  Birmingham, UK (10th March 2023) – Histofy, a spinout company from the University of Warwick, today announces it has joined hands with leading academic and clinical partners on a National Institute for Health and Care Research (NIHR) funded project to transform colon biopsy screening with advanced AI. The pioneering technology will automatically screen out normal biopsies so that pathologists can better use their resources analysing disease. The company, founded by Prof David Snead, Prof Nasir Rajpoot and Dr Simon Graham, will integrate its existing AI technology into clinical practice and perform an extensive validation using over ten thousand biopsy samples across ten UK sites. Easing the Staffing Crisis with AI ​​Increasing screening rates for early detection of colon cancer are placing significant pressure on already understaffed and overloaded histopathology resources worldwide. The surging demand ultimately leads to delays in diagnosis, negatively impacting patient care especially for those with abnormal conditions (e.g., cancer or serious inflammation) where early intervention and treatment are critical. The funding acquired from NIHR will enable Histofy to integrate AI into the screening procedure, helping to ease the tremendous pressure currently placed on pathologists.  “Current practice is unsustainable and with increasing demands for colon screening there is no sign of it slowing down” A Consortium of Ten Partners NIHR have funded £2.6 million over three years to a consortium of eleven UK organisations, where Histofy have secured over £500K as the sole commercial partner responsible for productising the technology and integrating it within existing hospital systems. The consortium comprises ten NHS sites: Coventry, Nottingham, Cambridge, Oxford, Southampton, Glasgow, Newcastle, Durham, North Tees and Wolverhampton, who will provide a total of ten thousand biopsy samples for large-scale validation of the algorithm.  Prof Snead, Chief Medical Officer at Histofy and the COBIx Project Lead, said: “I am excited at the prospect of streamlining the examination of colon biopsies using AI. Current practice is unsustainable and with increasing demands for colon screening there is no sign of it slowing down. Our AI technology will reduce the number of biopsies that require examination and hence help overcome current challenges with staffing”. Prof Rajpoot, Chief Scientific Officer at Histofy and the COBIx Joint Project Lead, added: “There is great potential for AI in pathology. In particular, our revolutionary technology can significantly reduce the burden of colon biopsy screening, helping pathologists focus on cases that require special attention”.  About NIHR The National Institute for Health and Care Research funds and delivers world-leading health and social care research that improves people’s health and wellbeing, and promotes economic growth. Their mission is to improve the health and wealth of the nation through research By Simon Graham Co-Founder and Chief Technology Officer

Histofy today announces the signing of spinout agreement with the University of Warwick to commercialise cutting-edge artificial intelligence (AI) tools for pathology.  Birmingham, UK (8th March 2023) – Histofy, a medical technology company specialising in developing transparent AI models for pathology, has announced that it is now a spinout from the University of Warwick. The company’s technology aims to revolutionise tissue based research and practice by bringing AI technologies for deep tissue profiling to the market. An Important Milestone The spinout from the University of Warwick marks an important milestone for Histofy, as it enables the company to develop and commercialise its innovative technology. The founding team of medical and AI experts is dedicated to driving innovation in the pathology field through the use of transparent AI models. Tim Francis, Business Development Manager at Warwick Innovations, said: “This is an important step in the realisation of technology developed at Warwick. There is great potential for improvements in cancer treatment and patient outcomes.” Cutting-Edge AI for Cellular Pathology Histofy’s innovative technology brings avant-garde AI to histopathology and offers precise and accurate tissue profiling that will enable faster and more accurate diagnostics, prognostics and predictive analytics. With a focus on the clinical and biopharma markets, the company’s technology has the potential to improve patient outcomes and reduce healthcare costs. “Our AI tools will leverage the huge amount of pathology data that exists worldwide and ultimately lead to faster diagnosis and better treatment” Prof Nasir Rajpoot, Chief Scientific Officer at Histofy, said: “I am excited for Histofy to pioneer the clinical translation of AI based biomarkers for improved diagnosis, prognosis and treatment selection. Our AI tools will leverage the huge amount of pathology data that exists worldwide and ultimately lead to faster diagnosis and better treatment”.  Prof David Snead, Chief Medical Officer at Histofy, stated: “I firmly believe in the tremendous potential of AI in pathology. The technology that Histofy is creating will transform the future of pathology, leading to more objective diagnosis, personalised medicine and shorter turnaround times”.  Histofy’s groundbreaking technology has already gained recognition in the medical community, with the founding team publishing over 250 papers in esteemed journals. The spinout from the University of Warwick further strengthens the company’s position in the market, as it continues to explore new ways of tissue profiling. Dr Simon Graham, Chief Technology Officer at Histofy, said:  “At Histofy we are looking forward to placing AI in the hands of biomedical researchers and practitioners to improve patient care. We are ready to make AI accessible across a range of solutions for the digital pathology market and believe that our technology will dramatically improve the management of complex diseases, such as cancer”.  By Nasir Rajpoot Co-Founder and Chief Scientific Officer

Histofy, a Birmingham-based startup, has been founded to accelerate the transformation of cancer research and care with cutting-edge transparent artificial intelligence (AI) technology. Birmingham, UK (6th February 2023) – Histofy AI, a UK-based startup, has been founded by a team of world leading experts with an accumulated 40+ years of experience in the field of digital pathology and AI. With over 250 publications in leading journals and conferences from research spanning over 20 years, the team brings their understanding of pathology and AI to  spearhead the development and introduction of advanced AI tools for clinical pathology and pharmaceutical research.  Transforming Pathology with AI Examination of pathology slides is essential in ensuring accurate diagnosis and appropriate treatment of many diseases, such as cancer. For many years, this has been done by visual inspection of the tissue with a microscope, but the digital pathology revolution means AI can be utilised to assist pathologists in delivering quicker and more accurate results – ultimately leading to better patient care.  Histofy has been launched to commercialise the AI tools the team has developed in research programmes over the past few years. This technology delivers transparent AI for deep profiling and interpretable decision-making from digitised images of pathology slides. “This is a very exciting time for pathology as we move into an era where pathologists will be using AI to assist in analysing patient tissue samples” Histofy Appoints CTO Today, Histofy also announces the appointment of Dr Simon Graham as the company’s Chief Technology Officer. With a background in mathematics and computer science, Dr Graham completed his PhD in computational pathology from the world-leading Tissue Image Analytics (TIA) Centre at the University of Warwick, where he was awarded the best thesis prize in the Faculty of Science, Engineering and Medicine.  Dr Graham, Chief Technology Officer at Histofy, said: “I am excited at the prospect of placing robust AI solutions in the hands of pathology and oncology researchers and practitioners to improve patient care. We are ready to make AI accessible across a range of solutions for the digital pathology market and believe that our technology will dramatically improve the management of diseases, such as cancer”.  Prof David Snead said:  “This is a very exciting time for pathology as we move into an era where pathologists will be using AI to assist in analysing patient tissue samples. Our research programme has developed some of the best and most interesting solutions. Histofy AI has been launched to take these technologies through productisation and commercialisation. Dr Simon Graham is a world leading computational pathology scientist developing this technology, so we are delighted to welcome him as our CTO.”  By David Snead Co-Founder and Chief Medical Officer